Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + Lisocabtagene Maraleucel in R/R Aggressive B-cell Lymphomas
NCT05583149Phase 2Active, not recruiting
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in aggressive B-cell lymphoma. Started Mar 2023; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT05583149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583149.